Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.

Scheurer, J; Reisser, T; Leithäuser, F; Messmann, J J; Holzmann, K; Debatin, K-M; Strauss, G

Scheurer, J; Reisser, T; Leithäuser, F; Messmann, J J; Holzmann, K; Debatin, K-M; Strauss, G.

Affiliation

Scheurer J; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Reisser T; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Leithäuser F; Institute of Pathology, University Ulm, Ulm, Germany.
Messmann JJ; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Holzmann K; Genomic-Core Facility, University Ulm, Ulm, Germany.
Debatin KM; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Strauss G; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Clin Exp Immunol ; 202(3): 407-422, 2020 12.

Article de En | MEDLINE | ID: mdl-32681646

Sujet(s)
Mots clés

GVHD; GVT effect; MDSCs; allogeneic bone marrow transplantation; rapamycin

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Lymphocytes T / Transplantation de moelle osseuse / Sirolimus / Cellules myéloïdes suppressives / Maladie du greffon contre l'hôte / Immunité cellulaire / Tumeurs expérimentales Limites: Animals Langue: En Journal: Clin Exp Immunol Année: 2020 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google